Free Equity Delivery
Flat ₹10 per Trade in Intraday & F&O
Windlas Biotech IPO is a book build issue of ₹401.54 crores. The issue is a combination of fresh issue of 0.36 crore shares aggregating to ₹165.00 crores and offer for sale of 0.51 crore shares aggregating to ₹236.54 crores.
Windlas Biotech IPO bidding started from Aug 4, 2021 and ended on Aug 6, 2021. The allotment for Windlas Biotech IPO was finalized on Aug 11, 2021. The shares got listed on BSE, NSE on Aug 16, 2021.
Windlas Biotech IPO price band is set at ₹460.00 per share . The lot size for an application is 30. The minimum amount of investment required by an retail is ₹13,440 (30 shares). The lot size investment for sNII is 15 lots (450 shares), amounting to ₹2,07,000, and for bNII, it is 73 lots (2,190 shares), amounting to ₹10,07,400.
Dam Capital Advisors Ltd. is the book running lead manager and MUFG Intime India Pvt.Ltd. is the registrar of the issue.
Refer to Windlas Biotech IPO RHP for detailed Information.
| IPO Date | August 4, 2021 to August 6, 2021 |
| Listing Date | August 16, 2021 |
| Face Value | ₹5 per share |
| Issue Price Band | ₹448 to ₹460 per share |
| Issue Price Final | ₹460 per share |
| Lot Size | 30 Shares |
| Sale Type | Fresh Capital-cum-Offer for Sale |
| Total Issue Size | 87,29,023 shares (aggregating up to ₹401.54 Cr) |
| Fresh Issue | 35,86,956 shares (aggregating up to ₹165.00 Cr) |
| Offer for Sale | 51,42,067 shares of ₹5 (aggregating up to ₹236.54 Cr) |
| Issue Type | Bookbuilding IPO |
| Listing At | BSE, NSE |
| Share Holding Pre Issue | 1,82,07,419 shares |
| Share Holding Post Issue | 2,17,94,375 shares |
Windlas Biotech IPO offers total 87,29,023 shares. Out of which 43,64,510 (50.00%) allocated to QIB, 17,45,804 (20.00%) allocated to QIB, 13,09,354 (15.00%) allocated to NII, 30,55,159 (35.00%) allocated to RII and 26,18,706 (30.00%) allocated to Anchor investors.
| Investor Category | Shares Offered | Maximum Allottees |
|---|---|---|
| QIB Shares Offered | 43,64,510 (50.00%) | NA |
| − Anchor Investor Shares Offered | 26,18,706 (30.00%) | NA |
| − QIB (Ex. Anchor) Shares Offered | 17,45,804 (20.00%) | NA |
| NII (HNI) Shares Offered | 13,09,354 (15.00%) | NA |
| Retail Shares Offered | 30,55,159 (35.00%) | 1,01,838 |
| Total Shares Offered | 87,29,023 (100.00%) |
Windlas Biotech IPO opens on August 4, 2021, and closes on August 6, 2021.
| IPO Open Date | Wed, Aug 4, 2021 |
| IPO Close Date | Fri, Aug 6, 2021 |
| Tentative Allotment | Wed, Aug 11, 2021 |
| Initiation of Refunds | Thu, Aug 12, 2021 |
| Credit of Shares to Demat | Fri, Aug 13, 2021 |
| Tentative Listing Date | Mon, Aug 16, 2021 |
| Cut-off time for UPI mandate confirmation | 5 PM on Fri, Aug 6, 2021 |
Investors can bid for a minimum of 30 shares and in multiples thereof. The following table depicts the minimum and maximum investment by Individual Investors (Retail) and HNI in terms of shares and amount.
| Application | Lots | Shares | Amount |
|---|---|---|---|
| Retail (Min) | 1 | 30 | ₹13,800 |
| Retail (Max) | 14 | 420 | ₹1,93,200 |
| S-HNI (Min) | 15 | 450 | ₹2,07,000 |
| S-HNI (Max) | 72 | 2,160 | ₹9,93,600 |
| B-HNI (Min) | 73 | 2,190 | ₹10,07,400 |
Note : The value will be calculated using Equity Dilution = Share Holding Pre Issue - Share Holding Post Issue
Incorporated in 2001, Windlas Biotech Ltd is one of the leading companies in the pharmaceutical formulations contract development and manufacturing organizations (CDMO) segment in India. The company offers a range of CDMO services from product discovery to product development, licensing, and commercial manufacturing of generic products including complex generics.
It further sells its own branded products in the trade generics and OTC markets. Currently, the focus of the company is to launch complex generic products in the chronic therapeutic category related to lifestyle-related disorders. The business operates in 3 verticals; 1. CDMO Products and services, 2. Domestic trade generics and Over-the-counter (OTC) market (nutraceutical and health supplement products), and 3. Export.
Leading pharma companies i.e. Pfizer Ltd, Sanofi India Ltd, Cadila Healthcare Ltd, Emcure Pharmaceuticals Ltd, Eris Lifesciences Ltd, Intas Pharmaceuticals Ltd, and Systopic Laboratories Private Limited are some of the marquee customers of Windlas Biotech. Its manufacturing facilities are located at Dehradun with an installed operating capacity of 7,063.83 million tablets/ capsules, 54.46 million pouch/ sachet, and 61.08 million liquid bottles.
Competitive strengths
| Particulars | For the year/period ended (₹ in million) | ||||
|---|---|---|---|---|---|
| 31-Mar-21 | 31-Mar-20 | 31-Mar-19 | |||
| Total Assets | 2,961.23 | 3,384.88 | 2,981.80 | ||
| Total Revenue | 4,306.95 | 3,313.39 | 3,115.25 | ||
| Profit After Tax | 155.70 | 162.13 | 638.22 | ||
The Company Windlas Biotech IPO proposes to utilise the Net Proceeds from the Issue towards the following objects:
| S.No. | Objects of the Issue | Expected Amount (₹ in crores) |
|---|---|---|
| 1 | Purchase of equipment required for (i) capacity expansion of the existing facility at the Dehradun Plant – IV; and (ii) addition of injectables dosage capability at our existing facility at Dehradun Plant – II | 50.00 |
| 2 | Funding incremental working capital requirements of the Company | 47.56 |
| 3 | Repayment/prepayment of certain of the borrowings | 20.00 |
| 4 | General corporate purposes( | 34.60 |
[Dilip Davda] Despite growth in its top lines, WBL has posted declining trends for bottom lines in order to clear its slate. Based on its financial parameters, the issue is aggressively priced. All recent moves will take about two years to be on a fast forward mode. Thus it is purely a long term bet at the current valuations that discounts all near term positives. Cash surplus investors may consider it with a long term perspective. Read detail review...
| Listing Date | August 16, 2021 |
| BSE Script Code | 543329 |
| NSE Symbol | WINDLAS |
| ISIN | INE0H5O01029 |
| Final Issue Price | ₹460 per share |
Windlas Biotech Ltd.
40/1, Mohabewala Industrial Area,
Dehradun, 248110
Dehradun, Uttarakhand
Phone: +91 135 6608000
Email: grievance@windlasbiotech.com
Website: http://www.windlasbiotech.com/
MUFG Intime India Pvt.Ltd.
Phone: +91-22-4918 6270
Email: windlas.ipo@linkintime.co.in
Website: https://linkintime.co.in/Initial_Offer/public-issues.html
Windlas Biotech IPO is a main-board IPO of 87,29,023 equity shares of the face value of ₹5 aggregating up to ₹401.54 Crores. The issue is priced at ₹460 per share. The minimum order quantity is 30.
The IPO opens on August 4, 2021, and closes on August 6, 2021.
MUFG Intime India Pvt.Ltd. is the registrar for the IPO. The shares are proposed to be listed on BSE, NSE.
Zerodha customers can apply online in Windlas Biotech IPO using UPI as a payment gateway. Zerodha customers can apply in Windlas Biotech IPO by login into Zerodha Console (back office) and submitting an IPO application form.
Steps to apply in Windlas Biotech IPO through Zerodha
Visit Zerodha IPO Application Process Review for more detail.
The Windlas Biotech IPO opens on August 4, 2021 and closes on August 6, 2021.
Windlas Biotech IPO lot size is 30, and the minimum amount required for application is ₹13,800.
You can apply in Windlas Biotech IPO online using either UPI or ASBA as a payment method. ASBA IPO application is available in the net banking of your bank account. UPI IPO Application is offered by brokers who don't offer banking services. Read more detail about applying IPO online through Zerodha, Upstox, 5Paisa, Nuvama, HDFC Bank, and SBI Bank.
The finalization of Basis of Allotment for Windlas Biotech IPO will be done on Wednesday, August 11, 2021, and the allotted shares will be credited to your demat account by Friday, August 13, 2021. Check the Windlas Biotech IPO allotment status.
The Windlas Biotech IPO listing date is on Monday, August 16, 2021.
Useful Articles
RHP